Stanford Medicine’s announcement regarding its new upright proton therapy facility is an important milestone for the future of radiotherapy and very positive for TibaRay.
The announcement demonstrates that upright patient positioning and treatment using Leo Cancer Care’s system is no longer just a concept. It is now being used to treat real patients at one of the world’s leading cancer centers. This helps validate the clinical and practical foundation of the Leo platform, which is highly relevant as Leo moves toward integrating TibaRay’s Galactica™ linac technology for future treatment systems.
From TibaRay’s perspective, this is very encouraging. Proton therapy is powerful, but proton systems remain too expensive for most hospitals to adopt broadly. With TibaRay’s new class of highly efficient and compact linac as the radiation source for highly conformal X-ray therapy, the economics become much more compelling. A single TibaRay Galactica™ linac will be significantly more affordable, easier to deploy, and more scalable for hospitals around the world.
More importantly, TibaRay’s longer-term vision is not only to make radiotherapy more affordable, but also to enable the next generation of highly conformal FLASH therapy, eXactFLASH™, through an array of our next release of more powerful compact linacs. This creates the potential to move beyond simply treating cancer toward curing cancer more effectively and with fewer side effects.
Thinh Tran
CEO, TibaRay, Inc.
TibaRay is a medical technology company developing next-generation FLASH radiotherapy systems to improve cancer treatment outcomes worldwide.
